Viruses,
Journal Year:
2023,
Volume and Issue:
15(8), P. 1624 - 1624
Published: July 26, 2023
Background
Sotrovimab,
a
monoclonal
antibody
against
SARS-CoV-2,
is
used
as
pre-exposition
prophylaxis
(PrEP)
COVID-19,
but
monitoring
strategies
using
routine
test
systems
have
not
been
defined.
Methods
Twenty
kidney
transplant
recipients
without
antibodies
after
vaccination
received
500
mg
Sotrovimab.
Antibody
levels
were
quantified
over
eight
weeks
live-virus
neutralization
(BA1
and
BA2),
binding
assays
(TrimericS,
Elecsys,
QuantiVAC)
surrogate
virus
tests
(sVNTs;
TECOmedical,
cPass
NeutraLISA).
Results
Sotrovimab
neutralized
both
Omicron
subvariants
NT
titer
90
(+−50)
>
BA2
33
(+−15)
one
hour
post
infusion).
was
measurable
on
all
immunoassays,
although
prior
1:100
dilution
necessary
for
Elecsys
due
to
presumed
prozone
effect.
The
best
correlation
with
titers
found
QuantiVAC
TrimericS,
respective
R2
of
0.65/0.59
0.76/0.57
BA1/BA2.
showed
an
0.56/0.54
BA1/BA2,
respectively.
sVNT
values
increased
infusion
had
only
poor
(TECOmedical
cPass)
or
did
reach
positivity
thresholds
(NeutraLISA).
Conclusion
measurements
by
the
immunoassays
differences
in
limited
capacity.
We
do
recommend
sVNTs
SARS-CoV-2
The
capability
of
antibodies
to
neutralize
different
SARS-CoV-2
variants
varies
among
individuals
depending
on
the
previous
exposure
wild-type-
or
Omicron-specific
immunogens
by
mono-
bivalent
vaccinations
infections.
Such
profiles
neutralizing
(nAbs)
usually
have
be
assessed
laborious
live
virus-neutralization
tests
(NTs).
We
therefore
analyzed
whether
a
novel
multivariant
surrogate
virus
neutralization
test
(sVNT)
(adapted
from
commercial
microarray)
that
quantifies
antibody-mediated
inhibition
between
receptor
angiotensin-converting-enzyme
2
(ACE2)
and
variant-specific
receptor-binding
domains
(RBDs)
can
assess
activity
against
wild-type,
Delta
Omicron
BA.1,
BA.2
BA.5
(sub-)
after
booster
with
Omicron-adapted
vaccines
in
manner
similar
live-virus
NTs.
Indeed,
using
NTs
as
reference,
we
found
significant
correlation
NT
titers
levels
ACE2-RBD
binding
(p
<
0.0001,
r
≤
0.78
respectively).
Furthermore,
sVNTs
identified
higher
values
BA.1
vaccinated
than
those
monovalent
wild-type
vaccines.
Our
data
thus
demonstrate
ability
detect
nAbs
following
Journal of Immunological Methods,
Journal Year:
2023,
Volume and Issue:
524, P. 113586 - 113586
Published: Nov. 30, 2023
Severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
is
the
causative
agent
of
disease
2019
(COVID-19)
global
pandemic.
Rapid
and
sensitive
detection
virus
soon
after
infection
important
for
treatment
prevention
transmission
COVID-19,
antibodies
epidemiology,
assessment
vaccine
immunogenicity,
identification
natural
reservoir
intermediate
host(s).
Patient
nasal
or
oropharyngeal
swabs
saliva
used
in
conjunction
with
polymerase
chain
reaction
(PCR)
detect
SARS-CoV-2
RNA,
whereas
lateral
flow
immunoassays
(LFI)
proteins.
Enzyme-linked
immunosorbent
assays
(ELISA)
anti-SARS-CoV-2
blood.
Although
effective,
these
have
poor
sensitivity
(e.g.,
LFI)
are
labor
intensive
time
consuming
(PCR
ELISA).
Here
we
describe
development
rapid,
automated
ELISA-based
to
antigens
against
virus.
The
Simple
Plex™
platform
uses
rapid
microfluidic
kinetics
analyte
small
sample
volumes.
We
developed
three
<90-min
Plex
that
measure
either
immune
response
SARS-CoV-2,
including
neutralizing
antibodies,
serum
from
COVID-19
patients.
Vaccines,
Journal Year:
2024,
Volume and Issue:
12(4), P. 377 - 377
Published: April 1, 2024
Background:
COVID-19,
caused
by
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2),
has
now
become
endemic
and
is
currently
one
of
the
important
virus
infections
regularly
affecting
mankind.
The
assessment
immunity
against
SARS-CoV-2
its
variants
for
guiding
active
passive
immunization
SARS-CoV-2-specific
treatment
strategies.
Methods:
We
here
devised
a
novel
flow
cytometry-based
diagnostic
platform
cell-bound
antigens.
This
based
on
collection
HEK-293T
cell
lines
which,
as
exemplified
in
our
study,
stably
express
receptor-binding
domains
(RBDs)
S-proteins
eight
major
variants,
ranging
from
Wuhan-Hu-1
to
Omicron.
Results:
RBD-expressing
display
comparable
levels
RBD
surface
cells,
shown
with
anti-FLAG-tag
antibodies
directed
N-terminally
introduced
3x-FLAG
sequence
while
functionality
was
proven
ACE2
binding.
exemplify
usefulness
specificity
cell-based
test
direct
binding
IgG
IgA
SARS-CoV-2-exposed
and/or
vaccinated
individuals
which
assay
shows
wide
linear
performance
range
both
at
very
low
high
serum
antibody
concentrations.
In
another
application,
i.e.,
adsorption
studies,
proved
be
powerful
tool
measuring
ratios
individual
variant-specific
antibodies.
Conclusion:
have
established
toolbox
antigens,
may
considered
an
addition
armamentarium
tests,
allowing
flexible
quick
adaptation
new
concern.
medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2023,
Volume and Issue:
unknown
Published: June 12, 2023
Abstract
We
studied
the
development
of
SARS-CoV-2
pandemic
in
Finland
2020
and
evaluated
performance
two
surrogate
immunoassays
for
detection
neutralizing
antibodies
(NAbs).
The
dataset
consisted
12000
retrospectively
collected
samples
from
pregnant
women
their
1
st
trimester
throughout
2020.
All
were
initially
screened
IgG
with
spike
antibody
assay
(EIM-S1,
Euroimmun,
Lübeck,
Germany)
followed
by
confirmation
nucleocapsid
(Architect
SARS-CoV-2,
Abbott,
Illinois,
USA).
Samples
that
reactive
(positive
or
borderline)
both
assays
subjected
to
testing
commercial
NeutraLISA
(EIM)
cPass
TM
(GenScript
Biotech
Corporation,
Rijswijk,
Netherlands)
using
pseudoneutralization
(PNAbA)
as
a
golden
standard.
No
seropositive
cases
detected
between
January
March.
Between
April
December,
(EIM-S1
Abbott
positive)
NAb
(PNAbA
seroprevalences
0.4-1.4%.
showed
90%
55%
concordant
results
PNAbA
among
negative
49%
92%
positive
giving
better
specificity
but
lower
sensitivity
than
cPass.
To
conclude,
seroprevalence
reflected
general
population
variability
serological
protocols
needs
be
taken
into
account
inter-study
comparison.
Viruses,
Journal Year:
2023,
Volume and Issue:
15(8), P. 1624 - 1624
Published: July 26, 2023
Background
Sotrovimab,
a
monoclonal
antibody
against
SARS-CoV-2,
is
used
as
pre-exposition
prophylaxis
(PrEP)
COVID-19,
but
monitoring
strategies
using
routine
test
systems
have
not
been
defined.
Methods
Twenty
kidney
transplant
recipients
without
antibodies
after
vaccination
received
500
mg
Sotrovimab.
Antibody
levels
were
quantified
over
eight
weeks
live-virus
neutralization
(BA1
and
BA2),
binding
assays
(TrimericS,
Elecsys,
QuantiVAC)
surrogate
virus
tests
(sVNTs;
TECOmedical,
cPass
NeutraLISA).
Results
Sotrovimab
neutralized
both
Omicron
subvariants
NT
titer
90
(+−50)
>
BA2
33
(+−15)
one
hour
post
infusion).
was
measurable
on
all
immunoassays,
although
prior
1:100
dilution
necessary
for
Elecsys
due
to
presumed
prozone
effect.
The
best
correlation
with
titers
found
QuantiVAC
TrimericS,
respective
R2
of
0.65/0.59
0.76/0.57
BA1/BA2.
showed
an
0.56/0.54
BA1/BA2,
respectively.
sVNT
values
increased
infusion
had
only
poor
(TECOmedical
cPass)
or
did
reach
positivity
thresholds
(NeutraLISA).
Conclusion
measurements
by
the
immunoassays
differences
in
limited
capacity.
We
do
recommend
sVNTs
SARS-CoV-2
